SEC ownership of IMPACT BIOMEDICAL INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001834105.

Comparable stake leader

Heng Fai Ambrose Chan

Disclosed value leader

GEODE CAPITAL MANAGEMENT, LLC

Comparable rows

1/20

Latest evidence

07 Oct 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
1 of 20
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Heng Fai Ambrose Chan
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
07 Oct 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001834105
Issuer location
West Henrietta, NY

Ownership snapshot

Top shareholders of IMPACT BIOMEDICAL INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Heng Fai Ambrose Chan
Disclosed value leader
GEODE CAPITAL MANAGEMENT,...
Comparable rows
1/20
Latest evidence
07 Oct 2026
3/4/5 13D/G 13F Lead comparable stake: 2.9% 19 rows are not safely comparable across share classes. 13D/G row: Heng Fai Ambrose Chan Showing 1-8 of 20 holder rows.

Quick read

Heng Fai Ambrose Chan leads the comparable SEC ownership view at 2.9%.

1 of 20 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Heng Fai Ambrose Chan's linked filing trail.
Comparable ownership Top 1
Heng Fai Ambrose Chan 2.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 20 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Heng Fai Ambrose Chan
3/4/5 13D/G
Director, 10%+ Owner
2.9%
Reported 13D/G · 02 Apr 2025
$17,350
32,112 shares
— 07 Oct 2026
DSS, INC.
3/4/5
10%+ Owner
—
denominator unverified
$271,178
589,518 shares
-$398 22 Sep 2026
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$526,316
93,915 shares
— 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$413,028
73,755 shares
— 30 Sep 2026
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$272,782
48,711 shares
— 30 Sep 2026
VANGUARD FIDUCIARY TRUST CO
13F
Company
13F
—
denominator unverified
$261,554
46,706 shares
— 30 Sep 2026
Frank D. Heuszel
3/4/5
Chief Executive Officer, Director
—
denominator unverified
$219,783
97,344 shares
— 05 Dec 2024
Jason Grady
3/4/5
Director
—
denominator unverified
$162,643
28,164 shares
-$32,505 07 Oct 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$58,233.

Buys
$0
Insiders: 0
Sells
$58,233
Insiders: 3
Net
-$58,233
Shares: -95,723
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 95,723
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 723 $0 $398 -$398
3-6 0 0 $0 $0 $0
6-9 0 95,000 $0 $57,835 -$57,835
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-11 of 11 reporting-owner rows connected to IMPACT BIOMEDICAL INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
11
Largest Forms 3/4/5 holder
DSS, INC.
Net 12M change
-$58.23KFull value: -$58,233 · USD · 12-month change
Latest report
07 Oct 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
DSS, INC. 10%+ Owner $271,178 -$398 -0.15% Mixed 22 Sep 2026
Frank D. Heuszel Chief Executive Officer, Director $219,783 Filing P/S 05 Dec 2024
Jason Grady Director $162,643 -$32,505 -17% Mixed 07 Oct 2026
Todd D. Macko Chief Financial Officer $87,101 -$25,330 -23% Mixed 07 Oct 2026
Heng Fai Ambrose Chan Director, 10%+ Owner $17,350 Mixed 07 Oct 2026
Castel Berisford Hibbert Director $17,350 Mixed 07 Oct 2026
Mark Suseck Chief Operating Officer $17,350 Mixed 07 Oct 2026
Melissa Kaye Sims Director $17,350 Mixed 07 Oct 2026
David K. Keene Director $17,350 Mixed 07 Oct 2026
Elise Brownell Director $17,350 Mixed 07 Oct 2026
Christian Thomas Zimmerman Director $17,350 Mixed 07 Oct 2026

Recent insider transactions for IMPACT BIOMEDICAL INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Mark Suseck IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Christian Thomas Zimmerman IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Castel Berisford Hibbert IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Melissa Kaye Sims IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
David K. Keene IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Elise Brownell IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Heng Fai Ambrose Chan IBO Common Stock Award -11.5% -4,170 32,112 07 Oct 2026 Direct
Jason Grady IBO Common Stock Award -12.9% -4,170 28,164 07 Oct 2026 Direct
Todd D. Macko IBO Common Stock Award -20.2% -4,170 16,462 07 Oct 2026 Direct
Dss, Inc. IBO Common Stock Sale -0.03% -156 589,518 24 Sep 2026 Direct
Dss, Inc. IBO Common Stock Sale -27 589,674 23 Sep 2026 Direct
Dss, Inc. IBO Common Stock Sale -0.12% -$398 $0.5500 -723 589,701 22 Sep 2026 Direct
Todd D. Macko IBO Common Stock Sale -21.9% -$24,369 $0.5615 -43,400 155,122 27 Mar 2026 Direct
Todd D. Macko IBO Common Stock Sale -0.8% -$961 $0.6008 -1,600 198,122 25 Mar 2026 Direct
Jason Grady IBO Common Stock Sale -16.7% -$32,505 $0.6501 -50,000 250,182 23 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .